GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more
Market Cap & Net Worth: GeneFerm Biotechnology Co Ltd (1796)
GeneFerm Biotechnology Co Ltd (TWO:1796) has a market capitalization of $48.74 Million (NT$1.61 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #24593 globally and #1498 in its home market, demonstrating a -6.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GeneFerm Biotechnology Co Ltd's stock price NT$38.90 by its total outstanding shares 41459793 (41.46 Million).
GeneFerm Biotechnology Co Ltd Market Cap History: 2016 to 2026
GeneFerm Biotechnology Co Ltd's market capitalization history from 2016 to 2026. Data shows change from $93.80 Million to $48.74 Million (-7.39% CAGR).
GeneFerm Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GeneFerm Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
GeneFerm Biotechnology Co Ltd's market cap is 0.11 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $63.59 Million | $349.83 Million | $28.23 Million | 0.18x | 2.25x |
| 2018 | $49.70 Million | $357.45 Million | $10.31 Million | 0.14x | 4.82x |
| 2019 | $36.80 Million | $328.23 Million | -$27.55 Million | 0.11x | N/A |
| 2020 | $34.99 Million | $368.30 Million | $4.53 Million | 0.10x | 7.73x |
| 2021 | $53.47 Million | $522.33 Million | $57.41 Million | 0.10x | 0.93x |
| 2022 | $82.66 Million | $633.96 Million | $93.45 Million | 0.13x | 0.88x |
| 2023 | $93.35 Million | $793.77 Million | $124.62 Million | 0.12x | 0.75x |
| 2024 | $58.89 Million | $521.16 Million | -$22.53 Million | 0.11x | N/A |
Competitor Companies of 1796 by Market Capitalization
Companies near GeneFerm Biotechnology Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to GeneFerm Biotechnology Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
GeneFerm Biotechnology Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, GeneFerm Biotechnology Co Ltd's market cap moved from $93.80 Million to $ 48.74 Million, with a yearly change of -7.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$48.74 Million | -19.38% |
| 2025 | NT$60.46 Million | +2.66% |
| 2024 | NT$58.89 Million | -36.91% |
| 2023 | NT$93.35 Million | +12.94% |
| 2022 | NT$82.66 Million | +54.60% |
| 2021 | NT$53.47 Million | +52.78% |
| 2020 | NT$34.99 Million | -4.90% |
| 2019 | NT$36.80 Million | -25.96% |
| 2018 | NT$49.70 Million | -21.84% |
| 2017 | NT$63.59 Million | -32.20% |
| 2016 | NT$93.80 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of GeneFerm Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.74 Million USD |
| MoneyControl | $48.74 Million USD |
| MarketWatch | $48.74 Million USD |
| marketcap.company | $48.74 Million USD |
| Reuters | $48.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.